Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05367661
• Other study ID #: CHK336-01
• Status: Terminated
• Phase: Phase 1
• Start date: April 8, 2022
• Est. completion date: April 19, 2023

Study information

• Verified date: November 2023
• Source: Chinook Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 88
• Est. completion date: April 19, 2023
• Est. primary completion date: April 19, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

Healthy volunteers must meet all the following inclusion criteria to be randomized:

1. Male and female adults18 to 45years old, inclusive, at the time of consent.

2. Body mass index (BMI) between 19 and 32 kg/m2, inclusive, (between 30.0 and < 40.0 kg/m2 for SAD Cohort A8) at screening.

3. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants (male or female) who are of childbearing potential must agree to use highly effective contraception during the study. Female participants must continue to use highly effective contraception during the study for 30 days after the last dose of study drug. Female participants should not donate oocytes during this time. Male participants with female partners of childbearing potential must continue to use highly effective contraception during the study and for 90 days after the last dose of study drug. Male participants must agree not to donate sperm during this time. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.

4. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and Day -3 as well as a negative urine pregnancy test at Day 1 (predose). WOCBP must agree to undergo a pregnancy test during the study

5. Female participants not of childbearing potential must be either surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) or postmenopausal, defined as no menses for 12 months without an alternative medical cause, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the central laboratory's ranges.

6. Willing and able to provide informed consent and comply with all study visits and procedures including overnight stays in the clinic

7. Willing and able to comply with a pre-specified diet at least 72 hours prior to dose and throughout the study.

8. Negative urine drug, tobacco, and breath alcohol test result at screening and Day-3.

9. Have not used any nicotine-containing product within 3 months prior to the first study drug administration and who are willing to abstain throughout the study.

Exclusion Criteria:

Healthy volunteers must not meet any of the following exclusion criteria to be randomized

1. Any significant medical history including but not limited to hypertension, diabetes, cardiovascular disease, hemolysis, red blood cell disorders, and/or with clinically significant screening results outside the normal range for laboratory testing, vital signs, medical history, electrocardiograms (ECGs), physical examination as deemed by the investigator. Reticulocytes must be within normal range at screening and prior to dosing. Red blood cell (RBC), hemoglobin, and hematocrit must be within 5% of normal range at screening and prior to dosing.

2. Evidence of chronic kidney disease (CKD) defined by an estimated glomerular filtration rate (eGFR) less than 80 mg/mL/1.73m2 based on the CKD epidemiology collaboration (EPI) equation or the presence of proteinuria at screening and prior to dosing.

3. Have any known malignancy or history of malignancy, except for basal cell skin cancer that has been treated and with no evidence of recurrence for at least 3 months prior to the first study drug administration.

4. History of liver disease, Gilbert's syndrome, or abnormal liver function test (AST, ALT, total bilirubin) above the normal reference range at screening and prior to dosing.

5. Any active infection or acute illness within 30 days prior to the first study drug administration.

6. Major surgery or significant traumatic injury occurring within 28 days prior to first dose of study drug. If major surgery occurred > 28 days prior to first dose of study drug, individual must have recovered adequately from any toxicity and/or complications from the intervention prior to the first dose of study drug.

7. Supine systolic blood pressure <90 or >140 mmHg, supine diastolic blood pressure <50 or >95 mmHg, pulse rate <40 or >100 beats per minute (bpm), or elevated body temperature (>38ºC) at screening and check-in

8. History or presence of a clinically significant ECG abnormalities and QTcF >450 ms for males and >470 ms for females, prior to dosing.

9. Positive serology tests for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).

10. Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication (with the exception of oral contraceptives) within 7 days prior to the first study drug administration.

11. Treatment with another investigational product within 30 days prior to the first study drug administration or within the expected washout (~5 half-lives) of the investigational product

12. Prior exposure to CHK-336 (including Part A of this study).

13. History or presence of alcohol abuse or drug use within 30 days prior to the first study drug administration and throughout the study

14. Blood donation or significant blood loss within 60 days prior to the first study drug administration.

15. Pregnancy, intent to become pregnant during the course of the study, or lactating women.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• CHK336
Tablet
• Placebo
Tablet

Locations

Country	Name	City	State
United States	Medpace Clinical Pharmacology Unit	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Chinook Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of CHK-336 in HV	Incidence, nature, and severity of adverse events (AEs), adverse events of special interest (AESI), and serious adverse events (SAEs)	Up to 28 days
Secondary	Pharmacokinetic measure of Cmax	Maximum observed concentration of CHK -336 in plasma under fasted or fed condition	Up to 17 days
Secondary	Pharmacokinetic measure of Tmax	Time to maximum observed concentration of CHK-336 in plasma under fasted or fed condition	Up to 17 days
Secondary	Pharmacokinetic measure of AUC (0-8)	The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-8) of CHK-336 in plasma under fed or fasted condition	Up to 17 days
Secondary	Pharmacokinetic measure of AUC for up to 24 hours (AUC0-24)	The area under the concentration-time curve from time zero extrapolated to 24 hours post dose (AUC0-24) in plasma under fed or fasted condition	up to 17 days
Secondary	Pharmacokinetic measure of AUC for up to last measurable time point (AUC0-T)	The area under the concentration-time curve from time zero extrapolated to last measurable timepoint (AUC0-T) of CHK-336 in plasma under fed or fasted condition	up to 17 days
Secondary	Pharmacokinetic measure of apparent terminal half-life (t1/2)	Apparent terminal half-life (t1/2) of CHK-336 in plasma under fasted or fed condition	up to 17 days
Secondary	Pharmacokinetic measure of exposure accumulation ratios of CHK-336	The exposure accumulation defined as the ratio of last dose to single dose AUC0-24h with once a day dosing	up to 17 days
Secondary	Pharmacokinetic measure of exposure accumulation ratios (Cmax) for CHK-336	The exposure accumulation defined as the ratio of last dose to single dose Cmax with once a day dosing	up to 17 days
Secondary	Pharmacokinetic measure of the amount of CHK-336 excreted in urine	Measure the amount of CHK-336 excreted in urine under fasted condition	Up to 24 hours